Stockscreener 앱 받기
1.40
4.48%
0.06
전일 마감가:
$1.34
열려 있는:
$1.36
하루 거래량:
4.31M
Relative Volume:
0.72
시가총액:
$434.84M
수익:
$160.03M
순이익/손실:
$-128.58M
주가수익비율:
-3.2802
EPS:
-0.4268
순현금흐름:
$-121.21M
1주 성능:
+3.70%
1개월 성능:
+21.74%
6개월 성능:
-25.53%
1년 성능:
+6.87%
1일 변동 폭
$1.36
$1.43
1주일 범위
$1.30
$1.45
52주 변동 폭
$1.09
$2.73
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.40 | 434.84M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-06 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacific Biosciences of California Inc (PACB) Institutional Confidence - TradingKey
Pacific Biosciences of California Inc - TradingKey
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacific Biosciences of California Inc (PACB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pacific Biosciences of California Inc (PACB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pacific Biosciences of California Inc (PACB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacific Biosciences of California Inc (PACB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street? - Yahoo Finance
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California Company Profile & Introduction - Moomoo
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets - Yahoo Finance
Pacific Biosciences of California, Inc. 8-K Filing: 2020 Equity Incentive Plan Amendment, Stockholder Voting Results & Company Information (June 2026) – Minichart - Minichart
Pacific Biosciences (PACB) director receives 223,492 stock options at $1.58 strike - Stock Titan
Christopher Gibson (NASDAQ: PACB) receives 74,497 stock options grant - Stock Titan
PACIFIC BIOSCIENCES (PACB) director granted 223,492 stock options at $1.58 - Stock Titan
Director at Pacific Biosciences (PACB) receives 223,492 stock options grant - Stock Titan
PACB (PACB) director granted 223,492 stock options at $1.58 exercise price - Stock Titan
Pacific Biosciences reserves 16,000,000 additional shares under 2020 Equity Incentive Plan - TradingView
Director William W. Ericson granted 223,492 PACB options at $1.58 exercise price - Stock Titan
Director John Milligan receives 223,492 options at PacBio (PACB) - Stock Titan
PacBio (PACB) director Kathy Ordonez receives 223,492 stock options at $1.58 - Stock Titan
Pacific Biosciences (PACB) shareholders approve 16M-share equity plan increase and 2026 auditor - Stock Titan
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Zacks Investment Research
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks - The Globe and Mail
Insiders At Pacific Biosciences of California Sold US$1.3m In Stock, Alluding To Potential Weakness - Moomoo
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology - TradingView
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PACB Q1 2026 Earnings: EPS Beats Estimates, Stock Surges 14%Fiscal Year Earnings - newsline.com
PacBio (PACB) Launches New Sequencing Technology for Global Dist - GuruFocus
Pacbio Ships Sprq-Nx Chemistry and Multi-Use Smrt Cells for Revio Hifi Sequencing Platform Worldwide - marketscreener.com
PacBio ships new sequencing chemistry, cuts genome cost By Investing.com - Investing.com Canada
PacBio ships new sequencing chemistry, cuts genome cost - Investing.com
AI-tuned PacBio upgrade brings sub-$300 human genomes at scale - Stock Titan
Pacific Biosciences: Pressure Is Rising (NASDAQ:PACB) - Seeking Alpha
PACB (Pacific Biosciences of California) ROC % : -47.66% (As of Mar. 2026) - GuruFocus
Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
PacBio to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance
Pacific Biosciences of California sets $300 price point for 20x human genome sequencing on Revio - Traders Union
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology - TradingView
PACB Secures $7.2M in Seed Funding and Partners with Blank Bio - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology - BioSpace
AI lab Blank Bio raises $7.2M, teams with PacBio on tumor RNA - Stock Titan
PacBio tumbles after narrowing full-year revenue guidance - MSN
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):